18:30-20:00, Monday 10th October, Oslo Room, ESMO congress

The goal for this educational activity is to improve the awareness of “value of care” and magnitude of clinical benefit deriving from use of CDK 4-6 inhibitors in metastatic breast cancer patients.

After attending the symposium, participants will be able to understand:
How CDK 4/6 inhibitors work and can be best incorporated into treatment algorithms;
Available clinical trial data addressing safety, efficacy, quality of life and patient-reported outcomes measures, and implications on treatment decisions;
How to manage CDK4/6 inhibitor-related toxicities in the clinic;
How to improve healthcare provider-patient conversations when it comes to discussing new treatment options and how to enhance patient care through shared decision-making.

The content for this symposium will be based on life-like clinical scenarios framed in virtual patient journeys that mimic real-life clinical encounters. This format ensures that knowledge will be rooted in developing clinical practices with learners encouraged to draw from their own experiences.